HOUSTON, TX — April 3, 2002 — While studying the effectiveness of a combination chemotherapy for women with metastatic breast cancer that overexpresses the HER2 protein, researchers at the University of Texas M. D. Anderson Cancer Center found that a new blood test may someday be a promising predictor for how similar patients may respond to trastuzumab (Herceptin) monoclonal antibody therapy.
In the April 1 issue of the Journal of Clinical Oncology, M. D. Anderson researchers published for the first time that trastuzumab combined with docetaxel (Taxotere) is safe and effective in treating patients with HER2 over-expressing metastatic breast cancer. The HER2 gene is amplified in 20 to 30 percent of invasive breast cancers.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!